Biodegradable nanoparticles as theranostics of ovarian cancer: an overview

J Pharm Pharmacol. 2018 Apr;70(4):435-449. doi: 10.1111/jphp.12860. Epub 2018 Jan 30.

Abstract

Objectives: Above 10 million people are suffering from cancers every year. As per American Cancer Society, more than 22 440 new cases and 14 080 deaths were reported from ovarian cancer yearly worldwide. This review explores the current status, challenges and future perspectives of tumour-targeted theranostic nanoparticles (NPs).

Key findings: Most of the ovarian malignancy cases are uncovered after the disease is in a difficult state due to poor screening techniques and non-specific symptoms. In this manner, forceful and fruitful treatment is required that will indicate insignificant lethal impacts to solid tissue. In the current research, stealth biodegradable NPs are produced as vehicles for imaging and treatment of ovarian cancer as the controlled and targeted delivery of chemotherapeutic as well as imaging agents. To enhance the dependability of the colloidal suspension as well as to increase their circulation lifetime, NPs are introduced by incorporating the functional poly(ethylene glycol) on their surface, which also provides a site to conjugation of focusing on agents to ovarian tissue.

Summary: Biodegradable theranostic NPs can be fabricated and surface engineered without any alteration in drug-loading capacity, safety and efficacy. These NPs have shown promising results in imaging as well as treatment of ovarian cancer.

Keywords: biodegradable nanoparticles; ovarian cancer; theranostics.

Publication types

  • Review

MeSH terms

  • Animals
  • Clinical Trials as Topic / methods
  • Drug Carriers / administration & dosage
  • Drug Carriers / metabolism
  • Female
  • Humans
  • Nanoparticles / administration & dosage*
  • Nanoparticles / metabolism*
  • Ovarian Neoplasms / diagnosis
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / metabolism*
  • Theranostic Nanomedicine / methods*

Substances

  • Drug Carriers